Tonapofylline

CAS Number

• 340021-17-2

PubChem CID

• 216466

IUPHAR/BPS

• 5605

DrugBank

• DB12569

Tonapofylline

Identifiers
IUPAC name 3-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1-bicyclo[2.2.2]octanyl]propanoic acid
CAS Number	340021-17-2
PubChem CID	216466
IUPHAR/BPS	5605
DrugBank	DB12569
ChemSpider	187607
UNII	83VNU4U44T
KEGG	D09684
ChEBI	CHEBI:177398
ChEMBL	ChEMBL414157
CompTox Dashboard (EPA)	DTXSID30187611
Chemical and physical data
Formula	C22H32N4O4
Molar mass	416.522 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCCN1C2=C(C(=O)N(C1=O)CCC)NC(=N2)C34CCC(CC3)(CC4)CCC(=O)O
InChI InChI=1S/C22H32N4O4/c1-3-13-25-17-16(18(29)26(14-4-2)20(25)30)23-19(24-17)22-10-7-21(8-11-22,9-12-22)6-5-15(27)28/h3-14H2,1-2H3,(H,23,24)(H,27,28) Key:ZWTVVWUOTJRXKM-UHFFFAOYSA-N

Tonapofylline (BG-9928) is a drug which acts as a potent and selective antagonist for the adenosine A₁ receptor. It was developed as a potential agent for the treatment of heart failure by increasing sodium excretion by the kidneys, and reached Phase III human clinical trials, showing reasonable efficacy with a good safety profile. However, it was ultimately not adopted for medical use, though it continues to be used in research.^{[1][2][3][4][5][6][7]} Its activity as a phosphodiesterase inhibitor does not appear to have been tested, though most related xanthine derivatives are phosphodiesterase inhibitors as well as adenosine receptor antagonists.